BR112014014805A2 - processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona - Google Patents
processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexonaInfo
- Publication number
- BR112014014805A2 BR112014014805A2 BR112014014805A BR112014014805A BR112014014805A2 BR 112014014805 A2 BR112014014805 A2 BR 112014014805A2 BR 112014014805 A BR112014014805 A BR 112014014805A BR 112014014805 A BR112014014805 A BR 112014014805A BR 112014014805 A2 BR112014014805 A2 BR 112014014805A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- induced constipation
- processes
- compositions
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
resumo patente da invenção: "processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona". são apresentados aqui processos para tratamento ou prevenção de constipação induzida por opióide por administração de composições orais de metilnaltrexona. os processos são baseados, pelo menos em parte, na identificação de indivíduos que sejam particularmente suscetíveis a tal tratamento e as dosagens ótimas de tais composições orais para tratar ou prevenir a constipação induzida por opióide e, também, para minimizar a ocorrência de eventos adversos associados a tal tratamento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161577654P | 2011-12-19 | 2011-12-19 | |
PCT/US2012/070612 WO2013096444A1 (en) | 2011-12-19 | 2012-12-19 | Methods for treatment and prevention of opioid induced constipation using oral compositions of methylnaltrexone |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112014014805A2 true BR112014014805A2 (pt) | 2017-06-13 |
Family
ID=48669445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014014805A BR112014014805A2 (pt) | 2011-12-19 | 2012-12-19 | processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona |
Country Status (11)
Country | Link |
---|---|
US (2) | US20130317050A1 (pt) |
EP (1) | EP2793888A4 (pt) |
JP (2) | JP2015501849A (pt) |
KR (1) | KR20140107540A (pt) |
CN (2) | CN104254332A (pt) |
AU (3) | AU2012359013A1 (pt) |
BR (1) | BR112014014805A2 (pt) |
CA (1) | CA2859203C (pt) |
IL (1) | IL233266A0 (pt) |
MX (1) | MX2014007312A (pt) |
WO (1) | WO2013096444A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015191686A1 (en) * | 2014-06-10 | 2015-12-17 | Salix Pharmaceuticals, Inc. | Methods of administering methylnaltrexone |
WO2016061531A1 (en) * | 2014-10-17 | 2016-04-21 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
KR20180123136A (ko) * | 2016-03-29 | 2018-11-14 | 코로나리콘셉츠 엘엘씨 | 변비 치료용 제제 |
WO2023031955A1 (en) * | 2021-08-28 | 2023-03-09 | Redasani Vijayendrakumar Virendrakumar Ji | Oral pharmaceutical compositions of methylnaltrexone and salt thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS601128A (ja) * | 1983-06-15 | 1985-01-07 | Shionogi & Co Ltd | 作用持続型セフアクロル製剤 |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
CA2480814A1 (en) * | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Method for inhibiting bone resorption with an alendronate and vitamin d formulation |
SE0303135D0 (sv) * | 2003-11-25 | 2003-11-25 | Lipocore Holding Ab | Controlled food effect composition |
WO2007005780A2 (en) * | 2005-07-01 | 2007-01-11 | Dynogen Pharmaceuticals, Inc. | Compositions and methods for treating gastrointestinal hypomotility and associated disorders |
WO2009137086A1 (en) * | 2008-05-07 | 2009-11-12 | Nektar Therapeutics | Oral administration of peripherally-acting opioid antagonists |
CN101845047B (zh) * | 2009-12-31 | 2011-12-07 | 南京臣功制药有限公司 | 一种溴甲基纳曲酮的制备方法 |
AR080491A1 (es) * | 2010-03-11 | 2012-04-11 | Wyeth Llc | Formulaciones orales y sales lipofilicas de metilnaltrexona |
-
2012
- 2012-12-19 CA CA2859203A patent/CA2859203C/en active Active
- 2012-12-19 MX MX2014007312A patent/MX2014007312A/es unknown
- 2012-12-19 WO PCT/US2012/070612 patent/WO2013096444A1/en active Application Filing
- 2012-12-19 CN CN201280070087.9A patent/CN104254332A/zh active Pending
- 2012-12-19 AU AU2012359013A patent/AU2012359013A1/en not_active Abandoned
- 2012-12-19 JP JP2014548835A patent/JP2015501849A/ja active Pending
- 2012-12-19 CN CN201910609611.9A patent/CN110384701A/zh active Pending
- 2012-12-19 BR BR112014014805A patent/BR112014014805A2/pt not_active Application Discontinuation
- 2012-12-19 US US13/720,235 patent/US20130317050A1/en not_active Abandoned
- 2012-12-19 KR KR1020147020310A patent/KR20140107540A/ko not_active Application Discontinuation
- 2012-12-19 EP EP12860187.9A patent/EP2793888A4/en not_active Withdrawn
-
2014
- 2014-06-19 IL IL233266A patent/IL233266A0/en unknown
-
2017
- 2017-11-06 AU AU2017258808A patent/AU2017258808A1/en not_active Abandoned
-
2018
- 2018-10-19 JP JP2018197326A patent/JP2019048820A/ja active Pending
- 2018-11-30 US US16/206,570 patent/US20190231771A1/en not_active Abandoned
-
2019
- 2019-05-27 AU AU2019203694A patent/AU2019203694A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2017258808A1 (en) | 2017-11-23 |
JP2019048820A (ja) | 2019-03-28 |
NZ625863A (en) | 2016-11-25 |
MX2014007312A (es) | 2014-08-27 |
IL233266A0 (en) | 2014-08-31 |
CN104254332A (zh) | 2014-12-31 |
EP2793888A4 (en) | 2015-10-28 |
EP2793888A1 (en) | 2014-10-29 |
WO2013096444A1 (en) | 2013-06-27 |
JP2015501849A (ja) | 2015-01-19 |
CA2859203C (en) | 2020-08-25 |
AU2012359013A1 (en) | 2014-06-26 |
AU2019203694A1 (en) | 2019-06-20 |
CN110384701A (zh) | 2019-10-29 |
CA2859203A1 (en) | 2013-06-27 |
KR20140107540A (ko) | 2014-09-04 |
US20190231771A1 (en) | 2019-08-01 |
US20130317050A1 (en) | 2013-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018005454A2 (pt) | administração de potencializadores de cftr deuterados | |
MY141025A (en) | Dose forms | |
EA201490254A1 (ru) | Комбинированное лечение гепатита с | |
BR112015014458A2 (pt) | derivados de manose para o tratamento de infecções bacterianas | |
WO2013024282A3 (en) | Inhibitor or down- regulator of the expression of one or both of tbk1 ikk-epsilon for use in the treatment of pi3kinase dependent cancer | |
MY162903A (en) | Methods of treatment of pancreatic cancer | |
EP2512479A4 (en) | METHOD AND COMPOSITIONS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
MA32784B1 (fr) | Composes aryles substitues par heterocycle comme inhibiteurs de hif | |
BR112014002141A2 (pt) | crizotinib para uso no tratamento de câncer | |
BRPI0606393A2 (pt) | prevenção de doenças trombóticas com compostos ativos de vitamina d ou similares do mesmo | |
AU2010266004A8 (en) | Method of treating cancer with Dll4 antagonist and chemotherapeutic agent | |
BR112013002541A2 (pt) | uso de ligante sigma, combinação de pelo menos um ligante sigma e de pelo menos um composto opióide ou opiato para administração simultânea, separada ou sequencial e método de tratamento de um paciente que sofre de oih associada à terapia opióide | |
WO2008043052A3 (en) | Human antibodies neutralizing human metapneumovirus | |
MX2017015012A (es) | Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné. | |
NZ744233A (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
MX367131B (es) | Sales de xantilio 3,6-disustituidas. | |
BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
BR112014014805A2 (pt) | processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona | |
BR112015001859A2 (pt) | tratamento de inflamação utilizando serelaxina | |
WO2010039742A3 (en) | Methods to reduce b-helper t cells to treat autoimmune diseases | |
BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . | |
MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
MX2011012538A (es) | Terapia de combinacion para el tratamiento del mieloma multiple. | |
BR112012029881A2 (pt) | combinação de anticorpos anti-envelope e anticorpos anti-receptor para o tratamento e a presenção de infecção por hcv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |